{"title":"Fda新药批准时间，处方药用户费用和研发支出","authors":"J. Golec, J. Vernon, R. Lutter, C. Nardinelli","doi":"10.2139/ssrn.931153","DOIUrl":null,"url":null,"abstract":"FDA-approval times have declined significantly since the enactment of the Prescription Drug User Fee Act (PDUFA) in 1992. As a result, present value expected returns to pharmaceutical RD thus, the social benefits of PDUFA (over and above the benefits of more rapid consumer access) are likely to be substantial.","PeriodicalId":297504,"journal":{"name":"Legislation & Statutory Interpretation","volume":"9 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2006-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"9","resultStr":"{\"title\":\"Fda New Drug Approval Times, Prescription Drug User Fees, and R&D Spending\",\"authors\":\"J. Golec, J. Vernon, R. Lutter, C. Nardinelli\",\"doi\":\"10.2139/ssrn.931153\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"FDA-approval times have declined significantly since the enactment of the Prescription Drug User Fee Act (PDUFA) in 1992. As a result, present value expected returns to pharmaceutical RD thus, the social benefits of PDUFA (over and above the benefits of more rapid consumer access) are likely to be substantial.\",\"PeriodicalId\":297504,\"journal\":{\"name\":\"Legislation & Statutory Interpretation\",\"volume\":\"9 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2006-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"9\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Legislation & Statutory Interpretation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2139/ssrn.931153\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Legislation & Statutory Interpretation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2139/ssrn.931153","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Fda New Drug Approval Times, Prescription Drug User Fees, and R&D Spending
FDA-approval times have declined significantly since the enactment of the Prescription Drug User Fee Act (PDUFA) in 1992. As a result, present value expected returns to pharmaceutical RD thus, the social benefits of PDUFA (over and above the benefits of more rapid consumer access) are likely to be substantial.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
